Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

University of Minnesota Researchers Find Evidence of Genetic Link to Breast Density

June 1, 1997
Publication
Article
OncologyONCOLOGY Vol 11 No 6
Volume 11
Issue 6

Researchers at the University of Minnesota Cancer Center have found evidence that mamographic breast density, a measure of the relative proportions of fat, connective tissue, and glandular epithelial tissue in the breast that is a strong, independent

Researchers at the University of Minnesota Cancer Center have foundevidence that mamographic breast density, a measure of the relative proportionsof fat, connective tissue, and glandular epithelial tissue in the breastthat is a strong, independent predictor of breast cancer risk, is geneticallyinfluenced. The study, published in the April 16th Journal of the NationalCancer Institute, also suggests that 12% of the population has a geneticmutation that results in a breast density twice that of women without themutation.

"It isn't known how high breast density increases the risk of breastcancer," said lead investigator Thomas Sellers, associate professorof epidemiology and associate director of the Cancer Center. "Butthe risk is considered second only to the risk incurred by mutations inthe BRCA1 and BRCA2 genes."

The researchers obtained routine mammograms and a variety of health-relateddata from 1,370 women from 258 different Minnesota families. The studypopulation included 65 mother-daughter pairs and 275 sister-sister pairs.All of the women were related, either genetically or by marriage, to anoriginal group of 544 breast cancer patients seen at the University ofMinnesota between 1944 and 1952. Sellers and colleagues are studying thesefamilies as part of the Breast Cancer Family Cohort study.

Breast Density Partly Modifiable

Sellers says that the study is significant because the researchers wereable to separate out other risk factors, such as waist-to-hip ratio, physicalactivity, hormone replacement therapy, and number of live births, to detecta Mendelian dominant inheritance pattern (a pattern where only one copyof the mutated gene is necessary to transfer the trait to offspring). Theywere unable, however, to completely eliminate the possibility of a recessivepattern, which would require more than one copy of a gene to produce atrait. However, if breast density is, indeed, controlled by a dominantgene, about 12% of the population would be expected to carry a form ofthe gene that results in a breast density about twice that of the restof the population. "The good news is that while breast density riskfactor is partly genetic, it's also shaped by the environment, and so canbe modified," Sellers said.

In previous studies, Sellers and colleagues have reported on potentialrisk factors for breast cancer, including waist-to-hip ratio, fat in thediet, and the connection between breast cancer in women and prostate cancerin men. These finding stem from the Iowa Women's Study, an ongoing healthstudy of more than 40,000 women in Iowa.

Articles in this issue

Use of Adjuvent Analgesics Profiled at Pain Conference
Chromosomal Changes Linked to Family History of Lung Cancer
Bacterial Infection in Patients With Cancer: Focus on Prevention
Docetaxel in Combined Modality Therapy for Breast Cancer
Role of Diet in Cancer Hard to Study, Expert Says
Anti-HIV Effects of Viracept Persist During Long Periods of Combination Therapy
University of Minnesota Researchers Find Evidence of Genetic Link to Breast Density
Guidelines for the Early Referral of Patients to Cancer Specialists
New Drugs May Brighten Ovarian Cancer Picture
Researchers Hope Function of BRCA1 Gene Holds Key to New Treatments
Research Points to Effectiveness of Brachytherapy in Early Prostate
Lung Cancer Surgical Practice Guidelines
Pituitary Adenomas: Current Methods of Diagnosis and Treatment
Management of Carcinoma of the Superior Pulmonary Sulcus
SSO Practice Guidelines: Introductory Remarks

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
2 experts in this video
Related Content

Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 (NCT03761108) trial.

Linvoseltamab Earns FDA Accelerated Approval for R/R Multiple Myeloma

Roman Fabbricatore
July 2nd 2025
Article

Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 trial.


Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.


Data from the HERIZON-BTC-01 trial evaluating zanidatamab in previously treated, unresectable HER2-positive biliary tract cancer support the decision.

Zanidatamab Receives EU Conditional Marketing Authorization in HER2+ BTC

Roman Fabbricatore
July 2nd 2025
Article

Data from the HERIZON-BTC-01 trial evaluating zanidatamab in previously treated, unresectable HER2-positive biliary tract cancer support the decision.


Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
June 23rd 2025
Podcast

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.


17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses

17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses

Daniella Natanov;Sharon Koehler
July 1st 2025
Article


The MALT1 inhibitor demonstrated a favorable safety profile and tolerability in findings from a phase 1 clinical trial presented at the EHA 2025 Congress.

SGR-1505 Earns Fast Track Designation for R/R Waldenström Macroglobulinemia

Roman Fabbricatore
July 1st 2025
Article

The MALT1 inhibitor demonstrated a favorable safety profile and tolerability in findings from a phase 1 clinical trial presented at the EHA 2025 Congress.

Related Content

Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 (NCT03761108) trial.

Linvoseltamab Earns FDA Accelerated Approval for R/R Multiple Myeloma

Roman Fabbricatore
July 2nd 2025
Article

Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 trial.


Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.


Data from the HERIZON-BTC-01 trial evaluating zanidatamab in previously treated, unresectable HER2-positive biliary tract cancer support the decision.

Zanidatamab Receives EU Conditional Marketing Authorization in HER2+ BTC

Roman Fabbricatore
July 2nd 2025
Article

Data from the HERIZON-BTC-01 trial evaluating zanidatamab in previously treated, unresectable HER2-positive biliary tract cancer support the decision.


Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
June 23rd 2025
Podcast

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.


17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses

17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses

Daniella Natanov;Sharon Koehler
July 1st 2025
Article


The MALT1 inhibitor demonstrated a favorable safety profile and tolerability in findings from a phase 1 clinical trial presented at the EHA 2025 Congress.

SGR-1505 Earns Fast Track Designation for R/R Waldenström Macroglobulinemia

Roman Fabbricatore
July 1st 2025
Article

The MALT1 inhibitor demonstrated a favorable safety profile and tolerability in findings from a phase 1 clinical trial presented at the EHA 2025 Congress.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.